Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given written consent to participate
- People between 50 and 85 years of age
- People who have been diagnosed with Mild Cognitive Impairment (some memory or thinking test results outside the normal range, but still able to manage daily activities) or mild dementia (difficulties with both thinking and daily activities)
- People who have had an MRI brain scan within the 6 months before the screening visit
- People for whom a doctor has ordered an amyloid PET scan (a brain imaging test that looks for a specific protein linked to Alzheimer's disease)
- People who are able and willing to follow the study requirements, as determined by the study investigator
Who may not be able to join:
- People who have a psychiatric disorder, significant white matter changes in the brain, or signs of a type of dementia caused by blood vessel problems
- People whose vision or hearing is not adequate for completing memory and thinking tests
- People who have previously taken part in a clinical trial for Alzheimer's disease that may have affected certain proteins in the brain
- People currently enrolled in other trials or studies that are not compatible with this study's brain imaging procedures (confirm with trial site)
- People who have metal implants or devices in their body that make MRI scanning unsafe
- Women who could become pregnant must not be pregnant (confirmed by a urine test on the day of imaging) or breastfeeding at the time of screening
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +41223727252
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference between tau-PET with [18F]RO948 and amyloid PET in the change of physician's diagnostic confidence (50-100% visual analogue scale) across time; Difference between tau-PET with [18F]RO948 and amyloid PET in the changes in etiological diagnoses across time (i.e., from Alzheimer disease (AD) to non-AD, or from non-AD to AD).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.